The Interaction Between Vasculogenic Mimicry and the Immune System: Mechanistic Insights and Dual Exploration in Cancer Therapy

Abstract

Vasculogenic mimicry (VM) represents a novel form of angiogenesis discovered in numerous malignant tumours in recent years. Unlike traditional angiogenesis, VM facilitates tumour blood supply independently of endothelial cells by enabling tumour cells to form functional vascular networks. This phenomenon, where tumour cells replace endothelial cells to form tubular structures, plays a pivotal role in tumour growth and metastasis. Tumour progression is influenced by a variety of factors, including immune components. The immune system serves as a critical defence mechanism by identifying and eliminating abnormal entities, such as tumour cells. This inevitably reminds us of the intricate connection between the immune system and VM. Indeed, in recent years, some studies have shown that immune responses and related immune cells play different regulatory roles in the formation of VM. Therefore, this review provides a comprehensive discussion on the mechanisms underlying VM formation, its interplay with the immune system, and the potential of leveraging immunotherapy to target VM.

Keywords

angiogenesis / immune system / tumour / vasculogenic mimicry

References

[1] Y. Wang, J. Li, Y. Gao, et al., “Hippo Kinases Regulate Cell Junctions to Inhibit Tumor Metastasis in Response to Oxidative Stress,” Redox Biology 26 (2019): 101233.

[2] J. Folkman, “Tumor Angiogenesis: Therapeutic Implications,” New England Journal of Medicine 285, no. 21 (1971): 1182-1186.

[3] J. J. Qiu, X. J. Lin, X. Y. Tang, T. T. Zheng, Y. Y. Lin, and K. Q. Hua, “Exosomal Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer,” International Journal of Biological Sciences 14, no. 14 (2018): 1960-1973.

[4] A. J. Maniotis, R. Folberg, A. Hess, et al., “Vascular Channel Formation by Human Melanoma Cells In Vivo and In Vitro: Vasculogenic Mimicry,” American Journal of Pathology 155, no. 3 (1999): 739-752.

[5] T. Xiang, Y. X. Lin, W. Ma, et al., “Vasculogenic Mimicry Formation in EBV-Associated Epithelial Malignancies,” Nature Communications 9, no. 1 (2018): 5009.

[6] J. Li and H. S. Lin, “Integrative Medicine: A Characteristic China Model for Cancer Treatment,” Chinese Journal of Integrative Medicine 17, no. 4 (2011): 243-245.

[7] J. Yang, “Using Nutrigenomics to Guide Personalized Nutrition Supplementation for Bolstering Immune System,” Health Information Science and Systems 11, no. 1 (2023): 4.

[8] H. Feng, Y. Zhao, W. Yan, et al., “Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning,” Frontiers in Medicine 9 (2022): 843749.

[9] J. Wang, W. Xia, Y. Huang, et al., “A Vasculogenic Mimicry Prognostic Signature Associated With Immune Signature in Human Gastric Cancer,” Frontiers in Immunology 13 (2022): 1016612.

[10] G. Morales-Guadarrama, R. García-Becerra, E. A. Méndez-Pérez, J. García-Quiroz, E. Avila, and L. Díaz, “Vasculogenic Mimicry in Breast Cancer: Clinical Relevance and Drivers,” Cells 10, no. 7 (2021): 1-17.

[11] J. Chen, S. Chen, L. Zhuo, Y. Zhu, and H. Zheng, “Regulation of Cancer Stem Cell Properties, Angiogenesis, and Vasculogenic Mimicry by miR-450a-5p/SOX2 Axis in Colorectal Cancer,” Cell Death & Disease 11, no. 3 (2020): 173.

[12] H. S. Kim, Y. J. Won, J. H. Shim, et al., “Morphological Characteristics of Vasculogenic Mimicry and Its Correlation With EphA2 Expression in Gastric Adenocarcinoma,” Scientific Reports 9, no. 1 (2019): 3414.

[13] E. A. Seftor, P. S. Meltzer, G. C. Schatteman, et al., “Expression of Multiple Molecular Phenotypes by Aggressive Melanoma Tumor Cells: Role in Vasculogenic Mimicry,” Critical Reviews in Oncology/Hematology 44, no. 1 (2002): 17-27.

[14] T. Xiao, Q. Zhang, S. Zong, et al., “Protease-Activated Receptor-1 (PAR1) Promotes Epithelial-Endothelial Transition Through Twist1 in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 185.

[15] A. Bettiol, S. Galora, F. R. Argento, et al., “Erythrocyte Oxidative Stress and Thrombosis,” Expert Reviews in Molecular Medicine 24 (2022): e31.

[16] J. Tímár, J. Tóth, B. Döme, and S. Paku, “Tumoral Sinuses or Vascular Channels in Tumors. Legacy of B. Kellner,” Magyar Onkologia 44, no. 2 (2000): 105-107.

[17] I. Camerino, P. Franco, A. Bajetto, et al., “Ruta Graveolens, but Not Rutin, Inhibits Survival, Migration, Invasion, and Vasculogenic Mimicry of Glioblastoma Cells,” International Journal of Molecular Sciences 25, no. 21 (2024): 105-107.

[18] K. Liu, B. Sun, X. Zhao, et al., “Hypoxia Promotes Vasculogenic Mimicry Formation by the Twist1-Bmi1 Connection in Hepatocellular Carcinoma,” International Journal of Molecular Medicine 36, no. 3 (2015): 783-791.

[19] M. Rezaei, A. C. Martins Cavaco, M. Stehling, et al., “Extracellular Vesicle Transfer From Endothelial Cells Drives VE-Cadherin Expression in Breast Cancer Cells, Thereby Causing Heterotypic Cell Contacts,” Cancers 12, no. 8 (2020): 1-25.

[20] A. C. Dudley and A. W. Griffioen, “Pathological Angiogenesis: Mechanisms and Therapeutic Strategies,” Angiogenesis 26, no. 3 (2023): 313-347.

[21] M. J. Hendrix, E. A. Seftor, R. E. Seftor, J. T. Chao, D. S. Chien, and Y. W. Chu, “Tumor Cell Vascular Mimicry: Novel Targeting Opportunity in Melanoma,” Pharmacology & Therapeutics 159 (2016): 83-92.

[22] D. Colak, O. Al-Harazi, O. M. Mustafa, et al., “RNA-Seq Transcriptome Profiling in Three Liver Regeneration Models in Rats: Comparative Analysis of Partial Hepatectomy, ALLPS, and PVL,” Scientific Reports 10, no. 1 (2020): 5213.

[23] J. R. Wilczyński and M. Duechler, “How Do Tumors Actively Escape From Host Immunosurveillance?,” Archivum Immunologiae et Therapiae Experimentalis (Warsz) 58, no. 6 (2010): 435-448.

[24] A. Chandra, J. Rick, G. Yagnik, and M. K. Aghi, “Autophagy as a Mechanism for Anti-Angiogenic Therapy Resistance,” Seminars in Cancer Biology 66 (2020): 75-88.

[25] K. Bajbouj, R. Qaisar, M. A. Alshura, et al., “Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer,” International Journal of Molecular Sciences 23, no. 8 (2022): 1-15.

[26] F. Li, Y. Shi, Y. Zhang, et al., “Investigating the Mechanism of Xian-Ling-Lian-Xia-Fang for Inhibiting Vasculogenic Mimicry in Triple Negative Breast Cancer via Blocking VEGF/MMPs Pathway,” Chinese Medicine 17, no. 1 (2022): 44.

[27] T. Xiao, W. Zhong, J. Zhao, et al., “Polyphyllin I Suppresses the Formation of Vasculogenic Mimicry via Twist1/VE-Cadherin Pathway,” Cell Death & Disease 9, no. 9 (2018): 906.

[28] O. Otero-Marquez, T. Y. Chui, A. Pinhas, et al., “3-D OCT Angiographic Evidence of Anti-VEGF Therapeutic Effects on Retinal Capillary Hemangioma,” American Journal of Ophthalmology Case Reports 25 (2022): 101394.

[29] D. Zhang, X. Yang, Z. Yang, et al., “Daughter Cells and Erythroid Cells Budding From PGCCs and Their Clinicopathological Significances in Colorectal Cancer,” Journal of Cancer 8, no. 3 (2017): 469-478.

[30] H. Sun, N. Yao, S. Cheng, et al., “Cancer Stem-Like Cells Directly Participate in Vasculogenic Mimicry Channels in Triple-Negative Breast Cancer,” Cancer Biology & Medicine 16, no. 2 (2019): 299-311.

[31] X. Pang, H. Y. Fan, Y. L. Tang, et al., “Myeloid Derived Suppressor Cells Contribute to the Malignant Progression of Oral Squamous Cell Carcinoma,” PLoS One 15, no. 2 (2020): e0229089.

[32] L. Huang, X. He, and X. Zuo, “The Effect and Mechanism of Curcumin Combined With Carboplatin Chemotherapy Promoting on Apoptosis of Lung Cancer HCC827 Cells,” Journal of Immunology Research 2022 (2022): 1932692.

[33] H. U. Rashid, Y. Xu, Y. Muhammad, L. Wang, and J. Jiang, “Research Advances on Anticancer Activities of Matrine and Its Derivatives: An Updated Overview,” European Journal of Medicinal Chemistry 161 (2019): 205-238.

[34] J. Zhang, M. Sun, M. Hao, et al., “FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner,” Frontiers in Oncology 9 (2019): 1244.

[35] H. Liang, L. Li, S. Zhu, et al., “MicroRNA-744-5p Suppresses Tumorigenesis and Metastasis of Osteosarcoma Through the p38 Mitogen-Activated Protein Kinases Pathway by Targeting Transforming Growth Factor-Beta 1,” Bioengineered 13, no. 5 (2022): 12309-12325.

[36] X. Dong, Y. Hong, H. Sun, C. Chen, X. Zhao, and B. Sun, “NDRG1 Suppresses Vasculogenic Mimicry and Tumor Aggressiveness in Gastric Carcinoma,” Oncology Letters 18, no. 3 (2019): 3003-3016.

[37] Y. H. Jin and S. A. Kim, “2-Methoxycinnamaldehyde Inhibits the TNF-α-Induced Proliferation and Migration of Human Aortic Smooth Muscle Cells,” International Journal of Molecular Medicine 39, no. 1 (2017): 191-198.

[38] L. Cheng, S. Li, K. He, et al., “Melatonin Regulates Cancer Migration and Stemness and Enhances the Anti-Tumour Effect of Cisplatin,” Journal of Cellular and Molecular Medicine 27, no. 15 (2023): 2215-2227.

[39] S. Wu, L. Yu, D. Wang, et al., “Aberrant Expression of CD133 in Non-Small Cell Lung Cancer and Its Relationship to Vasculogenic Mimicry,” BMC Cancer 12 (2012): 535.

[40] N. Eiro, L. O. Gonzalez, M. Fraile, S. Cid, J. Schneider, and F. J. Vizoso, “Breast Cancer Tumor Stroma: Cellular Components, Phenotypic Heterogeneity, Intercellular Communication, Prognostic Implications and Therapeutic Opportunities,” Cancers 11, no. 5 (2019): 1-26.

[41] C. Böckelman, I. Beilmann-Lehtonen, T. Kaprio, et al., “Serum MMP-8 and TIMP-1 Predict Prognosis in Colorectal Cancer,” BMC Cancer 18, no. 1 (2018): 679.

[42] J. Han, Y. Zhou, C. Zhang, et al., “Intratumoral Immune Heterogeneity of Prostate Cancer Characterized by Typing and Hub Genes,” Journal of Cellular and Molecular Medicine 27, no. 1 (2023): 101-112.

[43] S. Haiaty, M. R. Rashidi, M. Akbarzadeh, N. F. Maroufi, B. Yousefi, and M. Nouri, “Targeting Vasculogenic Mimicry by Phytochemicals: A Potential Opportunity for Cancer Therapy,” IUBMB Life 72, no. 5 (2020): 825-841.

[44] J. Lv, B. Sun, H. Sun, et al., “Significance of Vasculogenic Mimicry Formation in Gastric Carcinoma,” Oncology Research and Treatment 40, no. 1-2 (2017): 35-41.

[45] M. R. Xu, P. F. Wei, M. Z. Suo, et al., “Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231,” BioMed Research International 2019 (2019): 6543230.

[46] X. Zhao, B. Sun, T. Liu, et al., “Long Noncoding RNA n339260 Promotes Vasculogenic Mimicry and Cancer Stem Cell Development in Hepatocellular Carcinoma,” Cancer Science 109, no. 10 (2018): 3197-3208.

[47] H. H. Abd-Elhafeez, W. Abdo, B. M. Kamal, and S. A. Soliman, “Fish Telocytes and Their Relation to Rodlet Cells in Ruby-Red-Fin Shark (Rainbow Shark) Epalzeorhynchos frenatum (Teleostei: Cyprinidae),” Scientific Reports 10, no. 1 (2020): 18907.

[48] I. Chrifi, L. Louzao-Martinez, M. M. Brandt, et al., “CMTM4 Regulates Angiogenesis by Promoting Cell Surface Recycling of VE-Cadherin to Endothelial Adherens Junctions,” Angiogenesis 22, no. 1 (2019): 75-93.

[49] X. Lei, M. Chen, M. Huang, et al., “Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-Cadherin Internalization,” Theranostics 8, no. 2 (2018): 384-398.

[50] Y. Chen, D. Tang, L. Zhu, et al., “hnRNPA2/B1 Ameliorates LPS-Induced Endothelial Injury Through NF-κB Pathway and VE-Cadherin/β-Catenin Signaling Modulation In Vitro,” Mediators of Inflammation 2020 (2020): 6458791.

[51] M. J. Hendrix, E. A. Seftor, P. S. Meltzer, et al., “Expression and Functional Significance of VE-Cadherin in Aggressive Human Melanoma Cells: Role in Vasculogenic Mimicry,” Proceedings of the National Academy of Sciences of the United States of America 98, no. 14 (2001): 8018-8023.

[52] Y. Z. Fan and W. Sun, “Molecular Regulation of Vasculogenic Mimicry in Tumors and Potential Tumor-Target Therapy,” World Journal of Gastrointestinal Surgery 2, no. 4 (2010): 117-127.

[53] B. Cui, Y. Wang, J. Jin, et al., “Resveratrol Treats UVB-Induced Photoaging by Anti-MMP Expression, Through Anti-Inflammatory, Antioxidant, and Antiapoptotic Properties, and Treats Photoaging by Upregulating VEGF-B Expression,” Oxidative Medicine and Cellular Longevity 2022 (2022): 6037303.

[54] X. Ha, J. Wang, K. Chen, et al., “Free Fatty Acids Promote the Development of Prostate Cancer by Upregulating Peroxisome Proliferator-Activated Receptor Gamma,” Cancer Management and Research 12 (2020): 1355-1369.

[55] M. Balan, M. Trusohamn, F. C. Ning, et al., “Noninvasive Intravital High-Resolution Imaging of Pancreatic Neuroendocrine Tumours,” Scientific Reports 9, no. 1 (2019): 14636.

[56] G. Varricchi, G. Marone, and P. T. Kovanen, “Cardiac Mast Cells: Underappreciated Immune Cells in Cardiovascular Homeostasis and Disease,” Trends in Immunology 41, no. 8 (2020): 734-746.

[57] K. Ma, G. Singh, J. Wang, et al., “Targeting Vascular Endothelial Growth Factor Receptors as a Therapeutic Strategy for Osteoarthritis and Associated Pain,” International Journal of Biological Sciences 19, no. 2 (2023): 675-690.

[58] W. Sun, S. Fang, and H. Yan, “Discovery of Novel Picolinamide-Based Derivatives as Novel VEGFR-2 Kinase Inhibitors: Synthesis, In Vitro Biological Evaluation and Molecular Docking,” Medchemcomm 9, no. 6 (2018): 1054-1058.

[59] D. Jones, “Parallels of Resistance Between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy,” Cells 9, no. 3 (2020): 1-12.

[60] W. Hang, H. M. Guo, Q. L. Wu, H. Yan, G. Liu, and M. Gao, “MicroRNA-203a-3p Affects the Biological Characteristics of Nasopharyngeal Carcinoma by Targeting Vascular Endothelial Growth Factor-C,” Journal of Physiology and Pharmacology 72, no. 4 (2021): 605-613.

[61] R. Francescone, S. Scully, B. Bentley, et al., “Glioblastoma-Derived Tumor Cells Induce Vasculogenic Mimicry Through Flk-1 Protein Activation,” Journal of Biological Chemistry 287, no. 29 (2012): 24821-24831.

[62] R. Cheng, B. Wang, X. R. Cai, et al., “CD276 Promotes Vasculogenic Mimicry Formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs Pathway,” Oncotargets and Therapy 13 (2020): 11485-11498.

[63] D. Delgado-Bellido, E. Zamudio-Martínez, M. Fernández-Cortés, et al., “VE-Cadherin Modulates β-Catenin/TCF-4 to Enhance Vasculogenic Mimicry,” Cell Death & Disease 14, no. 2 (2023): 135.

[64] J. Sun, B. Sun, R. Sun, et al., “HMGA2 Promotes Vasculogenic Mimicry and Tumor Aggressiveness by Upregulating Twist1 in Gastric Carcinoma,” Scientific Reports 7, no. 1 (2017): 2229.

[65] C. Martini, M. DeNichilo, D. P. King, et al., “CD36 Promotes Vasculogenic Mimicry in Melanoma by Mediating Adhesion to the Extracellular Matrix,” BMC Cancer 21, no. 1 (2021): 765.

[66] Y. Leng, Z. Chen, H. Ding, X. Zhao, L. Qin, and Y. Pan, “Overexpression of microRNA-29b Inhibits Epithelial-Mesenchymal Transition and Angiogenesis of Colorectal Cancer Through the ETV4/ERK/EGFR Axis,” Cancer Cell International 21, no. 1 (2021): 17.

[67] L. N. Qin, H. Zhang, Q. Q. Li, et al., “Vitamin D Binding Protein (VDBP) Hijacks twist1 to Inhibit Vasculogenic Mimicry in Hepatocellular Carcinoma,” Theranostics 14, no. 1 (2024): 436-450.

[68] B. Fan, S. Shi, X. Shen, et al., “Effect of HMGN2 on Proliferation and Apoptosis of MCF-7 Breast Cancer Cells,” Oncology Letters 17, no. 1 (2019): 1160-1166.

[69] X. Wang, R. Yang, Q. Wang, Y. Wang, H. Ci, and S. Wu, “Aberrant Expression of Vasculogenic Mimicry, PRRX1, and CIP2A in Clear Cell Renal Cell Carcinoma and Its Clinicopathological Significance,” Medicine 98, no. 36 (2019): e17028.

[70] N. G. Gavalas, M. Tsiatas, O. Tsitsilonis, et al., “VEGF Directly Suppresses Activation of T Cells From Ascites Secondary to Ovarian Cancer via VEGF Receptor Type 2,” British Journal of Cancer 107, no. 11 (2012): 1869-1875.

[71] L. Xu, Y. Hu, and W. Liu, “Pyroptosis-Mediated Molecular Subtypes Are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer,” Journal of Inflammation Research 15 (2022): 345-362.

[72] B. Qu, G. Sheng, L. Guo, et al., “MIG7 Is Involved in Vasculogenic Mimicry Formation Rendering Invasion and Metastasis in Hepatocellular Carcinoma,” Oncology Reports 39, no. 2 (2018): 679-686.

[73] S. Saman, N. Srivastava, M. Yasir, and I. Chauhan, “A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer,” Current Cancer Drug Targets 24 (2023): 142-166.

[74] H. R. Lan, Y. N. Zhang, Y. J. Han, et al., “Multifunctional Nanocarriers for Targeted Drug Delivery and Diagnostic Applications of Lymph Nodes Metastasis: A Review of Recent Trends and Future Perspectives,” Journal of Nanobiotechnology 21, no. 1 (2023): 247.

[75] Q. Guo, Y. Yuan, Z. Jin, et al., “Association Between Tumor Vasculogenic Mimicry and the Poor Prognosis of Gastric Cancer in China: An Updated Systematic Review and Meta-Analysis,” BioMed Research International 2016 (2016): 2408645-2408648.

[76] D. Zhang, B. Sun, X. Zhao, et al., “Twist1 Accelerates Tumour Vasculogenic Mimicry by Inhibiting Claudin15 Expression in Triple-Negative Breast Cancer,” Journal of Cellular and Molecular Medicine 24, no. 13 (2020): 7163-7174.

[77] Y. S. Chen and Z. P. Chen, “Vasculogenic Mimicry: A Novel Target for Glioma Therapy,” Chinese Journal of Cancer 33, no. 2 (2014): 74-79.

[78] O. N. Hernández de la Cruz, J. S. López-González, R. García-Vázquez, et al., “Regulation Networks Driving Vasculogenic Mimicry in Solid Tumors,” Frontiers in Oncology 9 (2019): 1419.

[79] M. Huang, Y. Lin, C. Wang, et al., “New Insights Into Antiangiogenic Therapy Resistance in Cancer: Mechanisms and Therapeutic Aspects,” Drug Resistance Updates 64 (2022): 100849.

[80] A. K. Shum, J. DeVoss, C. L. Tan, et al., “Identification of an Autoantigen Demonstrates a Link Between Interstitial Lung Disease and a Defect in Central Tolerance,” Science Translational Medicine 1, no. 9 (2009): 9ra20.

[81] S. Song, C. Li, S. Li, H. Gao, X. Lan, and Y. Xue, “Derived Neutrophil to Lymphocyte Ratio and Monocyte to Lymphocyte Ratio May Be Better Biomarkers for Predicting Overall Survival of Patients With Advanced Gastric Cancer,” Oncotargets and Therapy 10 (2017): 3145-3154.

[82] J. Pinkas and B. A. Teicher, “TGF-Beta in Cancer and as a Therapeutic Target,” Biochemical Pharmacology 72, no. 5 (2006): 523-529.

[83] Y. Wu, Z. Peng, H. Wang, and W. Xiang, “Identifying the Hub Genes of Glioma Peritumoral Brain Edema Using Bioinformatical Methods,” Brain Sciences 12, no. 6 (2022): 1-11.

[84] M. M. Mohamed, E. A. El-Ghonaimy, M. A. Nouh, R. J. Schneider, B. F. Sloane, and M. El-Shinawi, “Cytokines Secreted by Macrophages Isolated From Tumor Microenvironment of Inflammatory Breast Cancer Patients Possess Chemotactic Properties,” International Journal of Biochemistry & Cell Biology 46 (2014): 138-147.

[85] G. Shu, S. Jiang, J. Mu, H. Yu, H. Duan, and X. Deng, “Antitumor Immunostimulatory Activity of Polysaccharides From Panax japonicus C. A. Mey: Roles of Their Effects on CD4+ T Cells and Tumor Associated Macrophages,” International Journal of Biological Macromolecules 111 (2018): 430-439.

[86] V. R. Juneja, K. A. McGuire, R. T. Manguso, et al., “PD-L1 on Tumor Cells Is Sufficient for Immune Evasion in Immunogenic Tumors and Inhibits CD8 T Cell Cytotoxicity,” Journal of Experimental Medicine 214, no. 4 (2017): 895-904.

[87] Z. Q. Chen, X. L. Zuo, J. Cai, et al., “Hypoxia-Associated circPRDM4 Promotes Immune Escape via HIF-1α Regulation of PD-L1 in Hepatocellular Carcinoma,” Experimental Hematology & Oncology 12, no. 1 (2023): 17.

[88] A. Vito, N. El-Sayes, and K. Mossman, “Hypoxia-Driven Immune Escape in the Tumor Microenvironment,” Cells 9, no. 4 (2020): 1-20.

[89] H. Zhang, Z. Dai, W. Wu, et al., “Regulatory Mechanisms of Immune Checkpoints PD-L1 and CTLA-4 in Cancer,” Journal of Experimental & Clinical Cancer Research 40, no. 1 (2021): 184.

[90] X. Pan, C. Li, and J. Feng, “The Role of LncRNAs in Tumor Immunotherapy,” Cancer Cell International 23, no. 1 (2023): 30.

[91] P. Wang, M. Tian, and W. Ren, “Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model,” Journal of Ultrasound in Medicine 41, no. 3 (2022): 713-723.

[92] Y. L. Fan, M. Zheng, Y. L. Tang, and X. H. Liang, “A New Perspective of Vasculogenic Mimicry: EMT and Cancer Stem Cells (Review),” Oncology Letters 6, no. 5 (2013): 1174-1180.

[93] R. Liu, K. Yang, C. Meng, Z. Zhang, and Y. Xu, “Vasculogenic Mimicry Is a Marker of Poor Prognosis in Prostate Cancer,” Cancer Biology & Therapy 13, no. 7 (2012): 527-533.

[94] D. Sun, B. Sun, T. Liu, et al., “Slug Promoted Vasculogenic Mimicry in Hepatocellular Carcinoma,” Journal of Cellular and Molecular Medicine 17, no. 8 (2013): 1038-1047.

[95] B. Shao, X. Zhao, T. Liu, et al., “LOXL2 Promotes Vasculogenic Mimicry and Tumour Aggressiveness in Hepatocellular Carcinoma,” Journal of Cellular and Molecular Medicine 23, no. 2 (2019): 1363-1374.

[96] Y. Huang, C. Zhu, P. Liu, et al., “L1CAM Promotes Vasculogenic Mimicry Formation by miR-143-3p-Induced Expression of Hexokinase 2 in Glioma,” Molecular Oncology 17, no. 4 (2023): 664-685.

[97] J. Liu, J. Huang, W. Y. Yao, et al., “The Origins of Vacularization in Tumors,” Front Biosci 17, no. 7 (2012): 2559-2565.

[98] K. Samadi and G. M. Salazar, “Role of Imaging in the Diagnosis of Vascular Malformations Vascular Malformations,” Cardiovascular Diagnosis and Therapy 9, no. Suppl 1 (2019): S143-s151.

[99] H. Kolesová, V. Olejníčková, A. Kvasilová, M. Gregorovičová, and D. Sedmera, “Tissue Clearing and Imaging Methods for Cardiovascular Development,” iScience 24, no. 4 (2021): 102387.

[100] C. M. Haggerty, A. P. Yoganathan, and M. A. Fogel, “Magnetic Resonance Imaging-Guided Surgical Design: Can We Optimise the Fontan Operation?,” Cardiology in the Young 23, no. 6 (2013): 818-823.

[101] R. Tabuchi, M. Anraku, D. Iohara, et al., “Surface-Deacetylated Chitin Nanofibers Reinforced With a Sulfobutyl Ether β-Cyclodextrin Gel Loaded With Prednisolone as Potential Therapy for Inflammatory Bowel Disease,” Carbohydrate Polymers 174 (2017): 1087-1094.

[102] S. Maly, L. Janousek, R. Bortel, et al., “NIRS-Based Monitoring of Kidney Graft Perfusion,” PLoS One 15, no. 12 (2020): e0243154.

[103] C. Wassef and B. K. Rao, “Uses of Non-Invasive Imaging in the Diagnosis of Skin Cancer: An Overview of the Currently Available Modalities,” International Journal of Dermatology 52, no. 12 (2013): 1481-1489.

[104] A. Z. Kyme, V. W. Zhou, S. R. Meikle, C. Baldock, and R. R. Fulton, “Optimised Motion Tracking for Positron Emission Tomography Studies of Brain Function in Awake Rats,” PLoS One 6, no. 7 (2011): e21727.

[105] T. Liu, X. Zhang, Y. Luo, Y. Huang, and G. Wu, “Slowly Delivered Icariin/Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells to Promote the Healing of Calvarial Critical-Size Bone Defects,” Stem Cells International 2016 (2016): 1416047.

[106] J. Zhang, S. Endres, and S. Kobold, “Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy,” Immunotherapy 11, no. 3 (2019): 201-213.

[107] M. H. Soheilifar, M. Grusch, H. K. Neghab, et al., “Angioregulatory microRNAs in Colorectal Cancer,” Cancers 12 (2019): 1.

[108] G. Laking and P. Price, “Radionuclide Imaging of Perfusion and Hypoxia,” European Journal of Nuclear Medicine and Molecular Imaging 37, no. Suppl 1 (2010): S20-S29.

[109] M. G. Ferlin, M. T. Conconi, L. Urbani, et al., “Synthesis, In Vitro and In Vivo Preliminary Evaluation of Anti-Angiogenic Properties of Some Pyrroloazaflavones,” Bioorganic & Medicinal Chemistry 19, no. 1 (2011): 448-457.

[110] Y. J. Li, X. Qing, Q. X. Tao, L. Xiang, L. Gong, and T. J. Zhou, “Vasculogenic Mimicry Formation Is Associated With Erythropoietin Expression but Not With Erythropoietin Receptor Expression in Cervical Squamous Cell Carcinoma,” BioMed Research International 2019 (2019): 1934195.

[111] R. Das, S. Langou, T. T. Le, P. Prasad, F. Lin, and T. D. Nguyen, “Electrical Stimulation for Immune Modulation in Cancer Treatments,” Frontiers in Bioengineering and Biotechnology 9 (2021): 795300.

[112] L. Zhao and Y. J. Cao, “Engineered T Cell Therapy for Cancer in the Clinic,” Frontiers in Immunology 10 (2019): 2250.

[113] A. J. Wolpaw, L. D. Grossmann, J. L. Dessau, et al., “Epigenetic State Determines Inflammatory Sensing in Neuroblastoma,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 6 (2022): 1-12.

[114] X. Chen, X. Xu, D. Wang, et al., “Neoadjuvant Sintilimab and Chemotherapy in Patients With Potentially Resectable Esophageal Squamous Cell Carcinoma (KEEP-G 03): An Open-Label, Single-Arm, Phase 2 Trial,” Journal for Immunotherapy of Cancer 11, no. 2 (2023): 1-11.

[115] G. Liu, C. Yuan, J. Ma, Y. Pan, and H. Xu, “Influence of Immune Microenvironment on Diagnosis and Prognosis of Head and Neck Squamous Cell Carcinoma,” Frontiers in Oncology 11 (2021): 604784.

[116] X. Jiang, L. Li, Y. Li, and Q. Li, “Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor,” Journal of Cancer 10, no. 7 (2019): 1764-1771.

[117] T. Yan, L. Yu, D. Shangguan, et al., “Advances in Pharmacokinetics and Pharmacodynamics of PD-1/PD-L1 Inhibitors,” International Immunopharmacology 115 (2023): 109638.

[118] T. Ranjan, V. Podder, K. Margolin, V. Velcheti, A. Maharaj, and M. S. Ahluwalia, “Immune Checkpoint Inhibitors in the Management of Brain Metastases From Non-Small Cell Lung Cancer: A Comprehensive Review of Current Trials, Guidelines and Future Directions,” Cancers 16, no. 19 (2024): 1-16.

[119] H. Yamaguchi, J. M. Hsu, W. H. Yang, and M. C. Hung, “Mechanisms Regulating PD-L1 Expression in Cancers and Associated Opportunities for Novel Small-Molecule Therapeutics,” Nature Reviews Clinical Oncology 19, no. 5 (2022): 287-305.

[120] Q. Rao, B. Zuo, Z. Lu, et al., “Tumor-Derived Exosomes Elicit Tumor Suppression in Murine Hepatocellular Carcinoma Models and Humans In Vitro,” Hepatology 64, no. 2 (2016): 456-472.

[121] L. He, Q. Kang, K. I. Chan, Y. Zhang, Z. Zhong, and W. Tan, “The Immunomodulatory Role of Matrix Metalloproteinases in Colitis-Associated Cancer,” Frontiers in Immunology 13 (2022): 1093990.

[122] R. Spisek and M. V. Dhodapkar, “Immunoprevention of Cancer,” Hematology/Oncology Clinics of North America 20, no. 3 (2006): 735-750.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.